How many drugs treat Abdominal abscess?

Drug Landscape tracks 10 marketed treatments for Abdominal abscess (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/abdominal-abscess.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Abdominal abscess — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abdominal abscess (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Abdominal abscess, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zerbaxa	CEFTOLOZANE	Cubist Pharms	Cephalosporin Antibacterial		2014-01-01
Doribax	DORIPENEM	Shionogi	Penem Antibacterial		2007-01-01
Tygacil	Tigecycline	Pfizer	Tetracycline	Bacterial protein synthesis	2005-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	beta Lactamase Inhibitor		1993-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Abdominal abscess
Merck Sharp & Dohme B.V. · 2 drugs in Abdominal abscess
Bayer AG · 2 drugs in Abdominal abscess
Merck & Co. · 2 drugs in Abdominal abscess
Pfizer · 2 drugs in Abdominal abscess
Fresenius Kabi · 1 drug in Abdominal abscess
Shionogi · 1 drug in Abdominal abscess
Assistance Publique - Hôpitaux de Paris · 1 drug in Abdominal abscess
National Institutes of Health Clinical Center (CC) · 1 drug in Abdominal abscess
Novartis Pharmaceuticals · 1 drug in Abdominal abscess
University of Oslo · 1 drug in Abdominal abscess
Baxter · 1 drug in Abdominal abscess

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Abdominal abscess:

Cite this brief

Drug Landscape (2026). Abdominal abscess — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/abdominal-abscess. Accessed 2026-06-10.

Abdominal abscess full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing